Market research
HBP.TO Helix BioPharma Corp
TO CAD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 76M
- P/E ratio
- Not available
- Analyst target
- 2.5
- Dividend yield
- Not available
- Beta
- -0.14
Profile
Instrument facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA4229101098
- Market cap
- 76M
- P/E ratio
- Not available
- Analyst target
- 2.5
- Dividend yield
- Not available
- Beta
- -0.14
About
About Helix BioPharma Corp
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Research context
Helix BioPharma Corp appears in PyInvesting’s Toronto Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the HBP.TO discussion.
5 years, 6 months ago
Helix BioPharma Corp is currently in a long term uptrend where the price is trading 36.8% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Helix BioPharma Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 11.7% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 37.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Helix BioPharma Corp gets an overall score of 2/5.